tbuckley/cabot-search huggingface dataset:
Kallikrein Inhibition for Hereditary Angioedema
Authors: Hilary J. Longhurst
Journal: New England Journal of Medicine (2017)

Management of hereditary angioedema due to C1 inhibitor deficiency has evolved. During the past 10 years, those affected have progressed from underrecognized disability and premature death, through evidence-based hospital treatment, toward self-administration and independence from unscheduled hospital care. Encouraging results from the use of lanadelumab for the prevention of angioedema associated with C1 inhibitor deficiency, reported by Banerji et al. in this issue of the Journal,1 promise a major step toward achieving this independence from ongoing medical care for all affected by the disorder.Hereditary angioedema is associated with unpredictable subcutaneous or submucosal swellings.2 These have a slow onset, last . . .
Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010
Authors: R.S. Herbst, P. Baas, D.-W. Kim, E. Felip, J.L. Pérez-Gracia, J.-Y. Han, J. Molina, J.-H. Kim, C. Dubos Arvis, M.-J.A. Ahn, M. Majem, M.J. Fidler, G. De Castro, M. Garrido, Y. Shentu, G.M. Lubiniecki, E.B. Garon
Journal: Annals of Oncology (2016)
Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302
Authors: Juliana M Benito, Volgin Y Andrei, Ye Chen, Lu Hongbo, Yuexi Shi, Teresa McQueen, Patrick A Zweidler-McKay, Damian R Handisides, Charles Hart, Michael Andreeff, Marina Konopleva
Journal: Blood (2012)
Large retroperitoneal lymphadenopathy (RPLN) and increased risk of venous thromboembolism (VTE) in patients (pts) with metastatic germ cell tumours (mGCT): a global germ cell cancer group (G3) study
Authors: B. Tran, J.M. Ruiz-Morales, E. González Billalabeitia, E. Amir, C. Seidel, C. Bokemeyer, C. Fankhauser, T. Hermanns, A. Rumyantsev, A. Tryakin, M. Brito, A. Flechon, D. Castellano, X. Garcia del Muro, A. Hamid, G. Palmieri, R. Kitson, A. Reid, D. Heng, P. Bedard
Journal: Annals of Oncology (2016)
The Impact of Race, Age, and Sex in Follicular Lymphoma (FL): A Comprehensive SEER Analysis in the Pre- and Post-Rituximab Eras
Authors: Chadi Nabhan, Briseis Aschebrook-Kilfoy, Brian C-H Chiu, Kimberly Kruczek, Anand Patel, Sonali M. Smith, Andrew M. Evens
Journal: Blood (2012)
Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm)
Authors: A. R. Townsend, M. Millward, T. Price, P. Mainwaring, A. Spencer, A. Longenecker, M. A. Palladino, G. K. Lloyd, M. A. Spear, P. Padrik
Journal: Journal of Clinical Oncology (2009)

3582 Background: The novel structure (non-peptide based) of NPI-0052 (NPI) appears to lead to unique proteasome inhibition (PI), toxicology and signal transduction profiles. Preclinical research suggests improvements in therapeutic ratio and activity in hematologic and solid tumor models, leading to clinical trials in patients with myeloma, lymphomas, leukemias, and solid tumors. Methods: Patients with solid tumor, lymphoma or leukemia diagnoses without standard treatment options were treated with IV NPI on Days 1, 8 and 15 of 28-day cycles in a 3+3 design dose escalation to a Recommended Phase 2 Dose (RP2D). Enrollment then began in 10 patient lymphoma and CLL RP2D cohorts. PI (D1 and D15) and PK (D1 and D15) were assayed. Results: 30 patients were treated at doses ranging from 0.1 mg/m 2 to 0.9 mg/m 2 . 0.7 mg/m 2 was selected as the RP2D secondary to DLT of transient “hallucinations” (visual imprints when eyes closed) and dizziness/unsteady gait at 0.9 mg/m 2 . At the RP2D fatigue, parosmia/dysgeusia, transient peri-infusion site pain and lymphopenia were commonly ascribed to NPI. At the RP2D PK data showed: half-life = 31 ± 28 min; AUC total = 270 ± 219 ng/mL*min; Cmax = 33.4 ± 34.2 ng/mL; clearance = 7.17 ± 0.40 L/min; volume of distribution (Vz) = 223.3 ± 229.7 L. PI was assayed in blood, indicating a dose:response relationship with mean inhibition of chymotrypsin-like activity up to of 88% Day 1 and 100% Day 15, and inhibition of caspase-like and trypsin-like activity of up to 51% and 72%. PI remained between doses in whole blood (RBC), but recovered between doses in PBMC. Stable disease was induced in 31% of patients, including one each with mantle cell, Hodgkin's lymphoma, follicular lymphoma, sarcoma, prostate carcinoma, and two with melanoma. Conclusions: NPI-0052 produces dose-dependent pharmacologic effects through the predicted efficacious range to an MTD, while producing a toxicity profile that is tolerable and dissimilar to bortezomib in spite of reaching higher PI levels. These data indicate potential for a greater range of uses than other proteasome inhibitors and lead to additional studies being initiated in hematologic malignancies and solid tumors alone and in combination. [Table: see text]
Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMS
Authors: J.-Y. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D.R. D'Adamo, M. Guo, R. Maki
Journal: Annals of Oncology (2016)
An Allosteric Modulator of PAR1 Demonstrates Selective Inhibition of G Protein Coupling and Impairs Thrombus Formation In Vivo
Authors: Omozuanvbo R Aisiku, Chris Dockendorff, Suzanne F Gunnick, Daniel A. Smith, James R. Dilks, Louisa M. Dowal, Robert C. Flaumenhaft
Journal: Blood (2011)
CSIG-27. AN RNAi KINOME SCREEN IDENTIFIES THE YES1 KINASE AS A POTENTIAL TARGET FOR GLIOBLASTOMA
Authors: Surbhi Goel-Bhattacharya, Sejuti Sengupta, Brent Cochran
Journal: Neuro-Oncology (2016)

We have conducted an RNAi kinome screen iofn glioblastoma stem-like cells (GSC) to identify genes that are required for their growth and survival. Since GBMs often have significant regions of hypoxia, we have conducted shRNA screens in both normoxic and hypoxic conditions and screened three independent patient derived GSC lines. Of the 504 kinases screened, 8-11% were scored as hits of which ~2 % (12) were common to all three the cell lines in both oxygen conditions. The majority of the hits were common to normoxia and hypoxia conditions, but a few were specific to hypoxia in each of the cell lines, None were hypoxia-specific for all cell lines. Several genes well-known to have a role in cancer and GBM such as CHEK1, PLK1 and KDR scored as common hits. None of the 12 common hits were frequently mutated in glioblastoma, but 7 of 12 were overexpressed in the GBM TCGA dataset. Higher expression of this common hit subset correlates with poor prognosis of GBM patients especially in the proneural subtype. The non-receptor associated tyrosine kinase YES1 scored as a novel hit common to all the three cell lines in both the oxygen conditions. YES1 is overexpressed in GBM in addition to variety of other solid tumors. Depletion of YES1 through shRNAs or CRISPR was found to be growth inhibitory in GSCs in vitro. Additionally, chemical inhibition of YES1 by SRC family kinase inhibitors were growth inhibitory to GSCs and induced apoptosis. Knockdown of YES1 in mouse xenografts extended survival. Chemical inhibition of the YES1 substrate YAP (Yes associated protein) also lead to GSC growth inhibition and induction of apoptosis suggesting that the YES/YAP signaling axis is required for GSC survival. Together, these results suggest that YES1 may be a novel therapeutic target for GBM.
Timing of Cardiac Magnetic Resonance Imaging Impacts on the Detection Rate of Left Ventricular Thrombus After Myocardial Infarction
Authors: Barnabas Gellen, Loïc Biere, Damien Logeart, Olivier Lairez, Eric Vicaut, Alain Furber, Jean-Jacques Mercadier, Marc Sirol
Journal: JACC. Cardiovascular imaging (2017)
Immunogenetic Characterization of Primary Immune Thrombocytopenia (ITP) in Adults: Preliminary Results of the Unit Study.
Authors: Francesco Zaia, Elena Boggio, Davide Rossi, Eleonora Toffoletti, Giuseppe Cappellano, Elisabetta Orilieri, Simona Puglisi, Monia Lunghi, Nicola Vianelli, Silvia Cantoni, Alessia Tieghi, Eloise Beggiato, Gianluca Gaidano, Renato Fanin, Umberto Dianzani
Journal: Blood (2012)
Final clinical results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/IV nonsquamous non-small cell lung cancer
Authors: R. Palmero, P. Bidoli, I.M. Bondarenko, M. Boyer, P. Germonpre, D. Ghizdavescu, A. Kotsakis, H. Lena, G. Losonczy, K. Park, M. Reck, W.-C. Su, N. Kallinteris, M. Tang, J. Lai, J. Shan, D.R. Spigel
Journal: Annals of Oncology (2017)
Histone Acetyltransferase Pcaf Is Required for ATRA-Induced Granulocytic Differentiation in Acute Promyelocytic Leukemia Cells
Authors: Yoshitaka Sunami, Marito Araki, Akihiro Ito, Yumi Hironaka, Minoru Yoshida, Akimichi Ohsaka, Norio Komatsu
Journal: Blood (2014)
Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
Authors: Vincent Muczynski, Gabriel Aymé, Véronique Regnault, Marc Vasse, Delphine Borgel, Paulette Legendre, Amine Bazaa, Amélie Harel, Cécile Loubière, Peter J. Lenting, Cécile V. Denis, Olivier D. Christophe
Journal: Blood (2017)
Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era
Authors: Lester A. Laddaran, Can-Lan Sun, Ari M. VanderWalde, Liton Francisco, Saro Armenian, Jennifer Berano Teh, F. Lennie Wong, Chatchada Karanes, Neil Martin Kogut, Amrita Krishnan, Auayporn Nademanee, Margaret O'Donnell, Pablo Parker, Leslie Popplewell, Anthony Selwyn Stein, Stephen J. Forman, Smita Bhatia
Journal: Blood (2010)
Interpenetrating Conducting Hydrogel Materials for Neural Interfacing Electrodes
Authors: Josef Goding, Aaron Gilmour, Penny Martens, Laura Poole‐Warren, Rylie Green
Journal: Advanced Healthcare Materials (2017)

Conducting hydrogels (CHs) are an emerging technology in the field of medical electrodes and brain-machine interfaces. The greatest challenge to the fabrication of CH electrodes is the hybridization of dissimilar polymers (conductive polymer and hydrogel) to ensure the formation of interpenetrating polymer networks (IPN) required to achieve both soft and electroactive materials. A new hydrogel system is developed that enables tailored placement of covalently immobilized dopant groups within the hydrogel matrix. The role of immobilized dopant in the formation of CH is investigated through covalent linking of sulfonate doping groups to poly(vinyl alcohol) (PVA) macromers. These groups control the electrochemical growth of the conducting polymer poly(3,4-ethylenedioxythiophene) (PEDOT) and subsequent material properties. The effect of dopant density and interdopant spacing on the physical, electrochemical, and mechanical properties of the resultant CHs is examined. Cytocompatible PVA hydrogels with PEDOT penetration throughout the depth of the electrode are produced. Interdopant spacing is found to be the key factor in the formation of IPNs, with smaller interdopant spacing producing CH electrodes with greater charge storage capacity and lower impedance due to increased PEDOT growth throughout the network. This approach facilitates tailorable, high-performance CH electrodes for next generation, low impedance neuroprosthetic devices.
Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in italy: a cross-section study
Authors: F. Roila, F. Spina, C. Ripamonti, G. Fumi, A. Antonuzzo, L. Cavanna, S. Gori, A. Mirabile, A. Fabi, N. Marzano, C. Graiff, V. De Sanctis, S. Serpentini, C. Bocci, M.S. Pino, G. Clienti, C. Verusio, S.E. Lutrino, S. Fatigoni, E. Ballatori
Journal: Annals of Oncology (2016)
New Algorithms for the Prediction of Cardiovascular Risk
Authors: Alan Rozanski, Daniel S. Berman
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
RTHP-16. MULTI-CRITERIA OPTIMIZATION FOR SRS OF MULTIPLE LESIONS BY SINGLE ISOCENTER USING TAGUCHI APPROACH COUPLED WITH PRINCIPAL COMPONENT ANALYSIS
Authors: Shlomi Alani, Nir Honig
Journal: Neuro-Oncology (2016)

This study utilizes the Taguchi Method to evaluate the VMAT planning parameters of single isocenter treatment plans for multiple brain metastases. An optimization model based on Taguchi and Principal component analysis is employed to optimize the planning parameters including: arc arrangement, calculation grid size, calculation model, and beam energy on multiple performance characteristics, namely conformity index and dose to normal brain. Treatment plans, each with 4 metastatic brain lesions were planned using single isocenter technique. The collimator angles were optimized to avoid open areas. In this analysis, four planning parameters (a-d) were considered: (a)-Arc arrangements: set1: Gantry 181cw179, couch0; gantry179ccw0, couch315; and gantry0ccw181, couch45. set2: set1 plus additional arc: Gantry 0cw179, couch270; (b)-Energy: 6-MV; 6MV-FFF; (c)-Calculation grid size: 1mm; 1.5mm; (d)-Calculation models: AAA; Acuros. Treatment planning was performed in Varian Eclipse (ver.11.0.30). A suitable orthogonal array was selected (L8) to perform the experiments. After conducting the experiments with the combinations of planning parameters, the conformity index (CI) and the normal brain dose S/N ratio for each parameter was calculated. Optimum levels for the multiple response optimizations were determined. We determined that the factors most affecting the conformity index are arc arrangement and beam energy. These tests were also used to evaluate dose to normal brain. In these evaluations, the significant parameters were grid size and calculation model. Using the utility concept we determined the combination of each of the four factors tested in this study that most significantly influence quality of the resulting treatment plans: (a)-arc arrangement-set2, (b)-6MV, (c)-calc.grid 1mm, (d)-Acuros algorithm. Overall, the dominant significant influences on plan quality are (a)-arcarrangement, and (b)-beamenergy. Results were analyzed using ANOVA and were found to be within the confidence interval. Further investigation using this methodology. Such parameters might include: virtual OAR and optimization criterion such as normal tissue objective.
Turning a challenge into an opportunity: pulmonary rehabilitation and socioeconomic deprivation
Authors: Kylie N Johnston, Marie T Williams
Journal: Thorax (2017)

The efficacy of pulmonary rehabilitation has been established for people with COPD such that the addition of further controlled clinical trials comparing pulmonary rehabilitation with usual care is considered unnecessary.1 ,2 How well the degree of health benefit reported within clinical trials of pulmonary rehabilitation translates into real-life settings is more difficult to ascertain. In real-world clinical environments, the effectiveness of pulmonary rehabilitation for people with COPD is likely to be confounded by heterogeneity in national healthcare systems, structure and staffing of rehabilitation programmes and participant characteristics of those referred to, accessing and completing pulmonary rehabilitation. While pragmatic clinical trials might provide local intelligence on pulmonary rehabilitation effectiveness, census-level surveys of clinical outcomes and sociodemographic data or pulmonary rehabilitation registries, such as those established in the USA3 and proposed in Australia4 permit associations between service provision, demographic characteristics and clinical outcomes to be explored at the population level.

The value of such population-level approaches is evident in the paper by Steiner and colleagues5 published in Thorax . Using data from the 2015 National COPD Clinical Audit Programme (England and Wales), Steiner and colleagues present an analysis of uptake and performance of participants across 230 pulmonary rehabilitation services,6 including over 7000 participants with COPD.7 Steiner and colleagues have reported that completion (defined as attending a discharge assessment) of pulmonary rehabilitation is lower in those with greater levels of socioeconomic deprivation. Where programmes are not ‘completed’, the optimal benefits of rehabilitation in terms of quality of life, breathlessness and exercise capacity are not expected to be gained. This is consistent with the results shown in other population-based studies where people with COPD and lower socioeconomic status attain poorer outcomes across the board, including greater mortality, more hospitalisations, less use …
Microrna-16 Regulates BMI1 in the Clonogenic Side Population of Refractory Mantle Cell Lymphoma
Authors: Kazuaki Teshima, Miho Nara, Atsushi Watanabe, Mitsugu Ito, Yoshiaki Hatana, Naoto Takahashi, Kouichi Oshima, Kenichi Sawada, Hiroyuki Tagawa
Journal: Blood (2012)
Smoking: Lung and Bladder Cancer
Authors: P. N. Lee
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article Smoking: Lung and Bladder Cancer Get access P. N. Lee, M.A. P. N. Lee, M.A. 25 Cedar Road Sutton, Surrey SM2 5DG, England Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 65, Issue 4, October 1980, Page 667, https://doi.org/10.1093/jnci/65.4.667 Published: 01 October 1980
Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors
Authors: Uday Popat, Roland Bassett, Leandro de Padua Silva, Amin M Alousi, Paolo Anderlini, Chitra M Hosing, Roy Jones, Partow Kebriaei, Issa Khouri, Elizabeth J Shpall, Muzaffar H Qazilbash, Guillermo Garcia-Manero, Borje S Andersson, Richard Champlin, Marcos J de Lima
Journal: Blood (2011)
BRAF, NRAS and C-KIT mutations segregate distinct clinical and histopathological profiles in patients with melanoma
Authors: S. Greco, R. Depenni, G. Ponti, D. Cerioli, E. Iattoni, F. Gelsomino, G. Luppi, M. Dominici, G. Pellacani, S. Cascinu
Journal: Annals of Oncology (2016)
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology
Authors: T. Okusaka, J.-F. Blanc, I. Chau, L. Yang, P. Abada, A.X. Zhu
Journal: Annals of Oncology (2016)
OS5.5 Supratotal resection in low grade gliomas (LGGs): feasibility and clinical impact
Authors: M. Rossi, M. Riva, C. Siodambro, G. Raccuia, A. Casarotti, P. Navarria, R. Soffietti, L. Bello
Journal: Neuro-Oncology (2016)

4 weeks versus 6.7 weeks in the BEV/LOM and LOM arm, respectively; p<0.001), reflecting the difference in time to progression between arms.
EXTH-24. TG02 SYNERGIZES WITH TEMOZOLOMIDE TO INHIBIT GLIOBLASTOMA GROWTH
Authors: Yu-Ting Su, Hua Song, Herui Wang, Virginia Rodriguez, Dragan Maric, Wei Zhang, Tracy Parrott, Tom Estok, Mark Gilbert, Jing Wu
Journal: Neuro-Oncology (2016)

Temozolomide (TMZ), one of the few effective therapies for glioblastoma, is known to induce apoptosis. However, its efficacy may be limited by MGMT expression, a major mechanism of TMZ resistance. TG02 is a multi-kinase inhibitor with a primary effect of inhibiting CDK9. The regulatory effects in cell cycle and apoptosis of TG02 have been demonstrated in other cancers, making TG02 a promising agent to study as a monotherapy and for its synergistic effect with TMZ in glioblastoma. Effects on cell proliferation were determined by using a Beckman Coulter cell viability analyzer following drug treatments in established cell lines: U87, U251, LN18, LN229; glioma-stem-cell lines: GSC923 and GSC827. Synergistic effects were determined by analyzing the combination index using the COMPUSYN software. Cell cycles were analyzed by FACS with EDU/violet staining. Western-blotting of lysate from drug-treated cells was performed to explore the mechanisms of treatment effects. The IC50 values of TG02 were between 20-214 nM in the selected cell lines. A synergistic effect was observed in both MGMT-methylated U251, and MGMT-unmethylated LN18 and GSC923, when treated with TG02/TMZ. Cell cycle analyses showed that TG02 induced S-phase arrest in U251 cells, which was enhanced following combination treatment with TMZ. Decreased expression of CDK9 and CDK9-transcriptionally-regulated proteins, such as Mcl-1, Survivin, and c-Myc was demonstrated in GSC923 following both TG02 and TG02/TMZ treatment. The cell apoptosis induced by both treatments was evidenced by an activation of caspase-3, phosphorylation of H2A.X and PARP cleavage. Glioblastoma cells are sensitive to TG02 treatment, regardless of the status of MGMT methylation. Combined TG02/TMZ treatment has a synergistic anti-glioma effect, primarily through enhancing apoptosis. This provides a promising therapeutic strategy to overcome the TMZ resistance in glioblastoma. Based on these results, a phase I/II study is planned in recurrent malignant glioma.
Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.
Authors: Devendra K Hiwase, Deborah L White, Jason A Powell, Verity A Saunders, Stephanie Zrim, Amity Frede, Mark Guthridge, Richard D'Andrea, L. Bik To, Junia V. Melo, Sharad Kumar, Timothy Hughes
Journal: Blood (2009)